Previous 10 | Next 10 |
Enrollment ahead of schedule in Phase 3 PROTECT Study of sparsentan in IgAN; topline proteinuria data from both pivotal studies in FSGS and IgAN now anticipated in 2021 Net product sales increased eight percent to $48 million in the second quarter Cash & equivalents of $457 m...
SAN DIEGO, July 16, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced it will report second quarter 2020 financial results on Thursday, July 30, 2020 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the finan...
SAN DIEGO, June 19, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Eric Dube, Ph.D., chief executive officer, will present at the BMO 2020 Prescriptions for Success Healthcare Conference on Tuesday, June 23, 2020 at 10:00 a.m. ET. A live webcast of the presen...
Quick Take Generation Bio ( GBIO ) intends to raise $126 million from the sale of its common stock in a U.S. IPO, per an amended registration statement . The company is a pre clinical developer of genetic treatments for liver and retinal diseases. GBIO is an ultra early stage biopharma ...
Retrophin (NASDAQ: RTRX ) has priced its public offering of 6.5M common shares at $15.50/share, for expected gross proceeds of ~$100.8M. More news on: Retrophin, Inc., Healthcare stocks news, , Read more ...
SAN DIEGO, June 08, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (Nasdaq: RTRX) today announced the pricing of an underwritten public offering of 6,500,000 shares of its common stock at a price to the public of $15.50 per share. All of the shares are being sold by Retrophin. The gross proceeds ...
SAN DIEGO, June 08, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (Nasdaq: RTRX) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering, subject to market and other conditions. All of the shares are being offered by Retrophin. In addition,...
SAN DIEGO, May 27, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Eric Dube, Ph.D., chief executive officer, will present at the Jefferies 2020 Virtual Healthcare Conference on Wednesday, June 3, 2020 at 2:30 p.m. ET. A live webcast of the presentation will ...
Image source: The Motley Fool. Retrophin (NASDAQ: RTRX) Q1 2020 Earnings Call May 11, 2020 , 4:30 p.m. ET Operator Continue reading
Retrophin, Inc. (RTRX) Q1 2020 Earnings Conference Call May 11, 2020 4:30 PM ET Company Participants Chris Cline – Senior Vice President-Investor Relations and Corporate Communications Eric Dube – Chief Executive Officer Noah Rosenberg – Chief Medical Officer...
News, Short Squeeze, Breakout and More Instantly...
SAN DIEGO, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Travere Therapeutics (NASDAQ: TVTX) today announced completion of patient enrollment in the Phase 3 DUPLEX Study. The pivotal DUPLEX Study is evaluating the safety and efficacy of sparsentan for the treatment of focal segmental glomerulosclerosis...
New name reflects dedication to patient- inspired mission of identifying, developing and delivering life-changing rare disease therapies Company’s s hares to t rade u nder n ew t icker s ymbol TVTX on Novem...
SAN DIEGO, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced the completion of its previously announced acquisition of Orphan Technologies Limited, a privately held, clinical-stage biopharmaceutical company focused on the development of product candidate OT-58...